Annovis Bio, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Annovis Bio, Inc. (ANVS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.90% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-03-21
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -1.90%.
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.40%.
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -1.50%, a 1600.00% decline from fiscal 2021.
- Annovis Bio, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -1.90% 10-K · filed 2025-03-21 |
| 2023-12-31 | -0.40% 10-K · filed 2025-03-21 |
| 2022-12-31 | -1.50% 10-K · filed 2024-03-29 |
| 2021-12-31 | 0.10% 10-K · filed 2023-03-31 |
| 2020-12-31 | -0.80% 10-K · filed 2022-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |